Hematology/Oncology

Top Story

Researchers develop value-based framework for cancer drug pricing

August 27, 2015

Researchers have developed a framework for establishing value-based pricing for new oncology drugs that are entering the U.S. market.

“Cancer drug prices have been skyrocketing in recent years, and these prices are not linked to the benefit that the drugs provide,” Daniel A. Goldstein, MD, a third-year fellow in the department of hematology and medical oncology at Winship Cancer Institute of Emory University, said in a press release. “Most new cancer drugs cost in excess of $10,000 per month.”

In the Journals

Overall global health improving, years lived with disability rising

August 27, 2015
Around the world, the average life expectancy increased by more than 6 years between 1990 and 2013; however, individuals are spending more years than ever living with…
In the Journals

Daratumumab demonstrates single-agent activity in relapsed, refractory multiple myeloma

August 27, 2015
Daratumumab monotherapy appeared safe and effective for patients with heavily pretreated relapsed or refractory multiple myeloma, according to study results published in…

CMS votes unanimously to maintain Medicare's reimbursement rate for Cologuard CRC screening test

August 27, 2015
The CMS Advisory Panel on Clinical Diagnostic Laboratory Tests voted unanimously (11-0) to maintain Medicare’s current reimbursement rate of $492.72 for the…
Mitch Zeller FDA News

FDA issues warning letter against tobacco manufacturers for ‘additive-free’ and ‘natural’ claims

August 27, 2015
The FDA has issued warning letters to three tobacco manufacturers that list cigarettes as “additive-free” and “natural” on the products’…
More News Headlines »
CME
Updates in Immunotherapy – Philadelphia 2015

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Immunotherapy Updates 2015: FOCUS on NSCLC

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »
morganatic-roan
morganatic-roan